INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Results

71,097 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
AR
Altschuler RandolphDirector
XMTRXometry, Inc.
Open-market sale · 10b5-1 plan
SELL$35K
330 sh
Nov 5, 2026Nov 6, 2026
Page 41 of 1778
← PrevNext →
traded Nov 5, 2026
+1d
SEC Form 4

Evidence

5
HC
Hite ChristopherEVP & Chairman, Partnering
RPRXRoyalty Pharma plc
Grant or award
A—
7,122 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

5
RR
Reske James REVP/Chief Financial Officer
FCFFIRST COMMONWEALTH FINANCIAL CORP /PA/
Open-market sale · 10b5-1 plan
SELL$2,195
100 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

5
MJ
Michaelson JenniferChief Scientific Officer
CGEMCullinan Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$49K
4,000 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

5
RR
Reske James REVP/Chief Financial Officer
FCFFIRST COMMONWEALTH FINANCIAL CORP /PA/
Open-market sale · 10b5-1 plan
SELL$3,058
140 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

5
RR
Reske James REVP/Chief Financial Officer
FCFFIRST COMMONWEALTH FINANCIAL CORP /PA/
Open-market sale · 10b5-1 plan
SELL$2,178
100 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

5
UM
Uychiat Pison MarivicDirector
ENSGENSIGN GROUP, INC
Grant or award
A—
4,000 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

5
RR
Reske James REVP/Chief Financial Officer
FCFFIRST COMMONWEALTH FINANCIAL CORP /PA/
Open-market sale · 10b5-1 plan
SELL$3,274
150 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

5
JK
Johnson Sandra K.Director
RMRegional Management Corp.
Open-market sale · 10b5-1 plan
SELL$27K
691 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

4
DP
Duffy Sean P.Director, Chief Executive Officer
OMDAOmada Health, Inc.
Open-market sale · 10b5-1 plan
SELL$249K
12.9K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

4
KA
King Ryan ADirector, Co-Founder
CHYMChime Financial, Inc.
Derivative conversion · 10b5-1 plan
C—
63.4K sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

4
MF
Mehmel Robert FPresident and COO
GFFGRIFFON CORP
Open-market sale · 10b5-1 plan
SELL$89K
825 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

4
DA
DelSanto AnneDirector
AEISADVANCED ENERGY INDUSTRIES INC
Open-market sale · 10b5-1 plan
SELL$53K
265 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

4
BD
Brown Christopher D.Director
MASS908 Devices Inc.
Open-market sale · 10b5-1 plan
SELL$329K
30.0K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

3
RA
Rothblatt Martine ADirector, Chairperson & CEO
UTHRUNITED THERAPEUTICS Corp
Option exercise · 10b5-1 plan
M—
9,500 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

3
ZM
Zerbe Robert L MdDirector
VCELVericel Corp
Option exercise · 10b5-1 plan
M$33K
2,500 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

3
MJ
Michaelson JenniferChief Scientific Officer
CGEMCullinan Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,805 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

2
PJ
Peters William JDirector, CFO, EVP & TREASURER
AMPHAmphastar Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$198K
11.0K sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

2
CT
Coxe TenchDirector
NVDANVIDIA CORP
Gift · 10b5-1 plan
G—
500.0K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
LB
Leach BryanDirector, CEO AND PRESIDENT, 10% Owner
IBTAIbotta, Inc.
Derivative conversion
C—
13.3K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
PJ
Pitofsky JasonSVP Controller
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise
M—
1,478 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Grant or award
A—
5,341 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Derivative conversion
C—
150.0K sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

2
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Grant or award
A—
7,122 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Derivative conversion
C—
100.0K sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

2
MK
Malady KyleEVP and Group CEO-VZ Business
VZVERIZON COMMUNICATIONS INC
Grant or award
A$1,738
132 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

2
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Derivative conversion
C—
150.0K sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

2
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Derivative conversion
C—
10.0K sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

2
PJ
Pitofsky JasonSVP Controller
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise
M—
905 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
LB
Leach BryanDirector, CEO AND PRESIDENT, 10% Owner
IBTAIbotta, Inc.
Derivative conversion
C—
13.3K sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

2
MV
Magliulo VirginiaExecutive VP
ADPAUTOMATIC DATA PROCESSING INC
Option exercise · 10b5-1 plan
M$176K
852 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

1
OP
O'Day Daniel PatrickDirector, Chairman & CEO
GILDGILEAD SCIENCES, INC.
Option exercise · 10b5-1 plan
M$710K
9,810 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

1
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$210K
7,881 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

1
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$103K
4,000 sh
Nov 4, 2026Nov 6, 2026
traded Nov 4, 2026
+2dSEC Form 4

Evidence

1
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$229K
8,400 sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

1
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$97K
3,481 sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC Form 4

Evidence

1
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$155K
5,926 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

1
DP
DIRK VAN DE PUTDirector, Chief Executive Officer
MDLZMondelez International, Inc.
Option exercise · 10b5-1 plan
M$909K
20.9K sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

1
RJ
Rubinstein JuliePresident and COO
ADPTAdaptive Biotechnologies Corp
Open-market sale · 10b5-1 plan
SELL$147K
5,455 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence

1
HJ
Hug JoshuaDirector
RELYRemitly Global, Inc.
Open-market sale · 10b5-1 plan
SELL$118K
5,500 sh
Nov 5, 2026Nov 6, 2026
traded Nov 5, 2026
+1dSEC Form 4

Evidence